- Schizophrenia: Cognitive therapy could be an effective treatment option for patients with schizophrenia unable to or refusing medication
- Autism: For providers and payers looking to update Autism treatment guidelines, check out the American Academy of Child and Adolescent Psychiatry latest recommendations, urging clinicians to take a multidisciplinary approach coordinated with a full physical exam and genetic workup
- Multiple Sclerosis: BCBS of North Carolina is now one year into a change in its Multiple Sclerosis utilization management guidelines for all commercial members and for all types of formularies: Injectables Avonex and Extavia and orals Aubagio and Gilenya are non-preferred while injectables Betaseron, Rebif and Copaxone and oral Tecfidera are preferred. To get a non preferred drug, a member or their doctor must first try and fail two different preferred medications (or, in the case of “orals”, at least try Tecfidera first)
- Alzheimer’s: Induced agitation may be treatable by a high dose of antidepressants according to research in a recent JAMA
- Panic Disorders: BCBS of TN encourages its network providers to use the American Psychiatric Association’s guidelines for treating panic disorder patients
